Current State of Monoclonal Antibody Therapy for Allergic Diseases

Abstract The prevalence of allergic diseases is increasing worldwide. Currently available biologic therapies have substantially enriched the therapeutic opportunities in the field of allergic diseases such as asthma, atopic dermatitis, and rhinosinusitis. The aims of the present review are to focus on the current status of development of monoclonal antibodies targeting the cytokines and immunoglobulin, which are involved in the pathogenesis of allergic diseases, and to discuss the clinical effects of these antibodies.